Ji Woong Bae, Um Jun Won, Ryu Je Seock, Hong Kwang Dae, Kim Jung Sik, Min Byung Wook, Joung Sung Yeop, Lee Ju Han, Kim Young Sik
Department of Surgery, Korea University Ansan Hospital, Gyeonggi-do, Republic of Korea.
Department of Surgery, Korea University Ansan Hospital, Gyeonggi-do, Republic of Korea
Anticancer Res. 2017 May;37(5):2679-2682. doi: 10.21873/anticanres.11616.
To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy.
Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay.
Fifty-one patients (57.3%) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemo-sensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups.
A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better disease-free survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/leucovorin chemotherapy.
评估化疗敏感性测试结果是否与接受辅助性5-氟尿嘧啶（FU）/亚叶酸钙化疗的结直肠癌患者的预后相关。
纳入89例接受5-FU/亚叶酸钙辅助化疗的结直肠癌患者。进行化疗敏感性测试，并使用MTT（3-(4,5-二甲基噻唑-2-基)-2,5-二苯基-2H溴化四唑）法计算肿瘤生长抑制率。
根据化疗敏感性测试，51例患者（57.3%）对5-FU敏感。中位随访64个月后，化疗敏感组和化疗耐药组的5年无病生存率存在显著差异。然而，化疗敏感组和化疗耐药组的5年总生存率无显著差异。
体外组织培养药物反应测定（HDRA）显示5-FU敏感性测试呈阳性与更好的无病生存率相关。化疗敏感性可能是接受辅助性5-FU/亚叶酸钙化疗的结直肠癌患者的一个预后因素。
